Valuation: Amgen Inc.

Capitalization 199B 172B 155B 149B 271B 18,307B 284B 1,833B 734B 8,779B 748B 732B 31,398B P/E ratio 2026 *
24.9x
P/E ratio 2027 * 22.9x
Enterprise value 239B 206B 186B 178B 325B 21,941B 340B 2,197B 880B 10,522B 896B 877B 37,631B EV / Sales 2026 *
6.31x
EV / Sales 2027 * 5.99x
Free-Float
99.85%
Yield 2026 *
2.72%
Yield 2027 * 2.9%
1 day+0.53%
1 week-4.80%
Current month-4.80%
1 month-3.85%
3 months+12.02%
6 months+30.28%
Current year+12.90%
1 week 361.4
Extreme 361.395
391.29
1 month 361
Extreme 361
391.29
Current year 318.21
Extreme 318.21
391.29
1 year 261.43
Extreme 261.43
391.29
3 years 211.71
Extreme 211.71
391.29
5 years 198.64
Extreme 198.64
391.29
10 years 133.64
Extreme 133.64
391.29
Manager TitleAgeSince
Chief Executive Officer 63 01/05/2012
Director of Finance/CFO 67 01/01/2020
Chief Operating Officer 59 25/07/2016
Director TitleAgeSince
Chairman 63 01/01/2013
Director/Board Member 65 01/01/2012
Director/Board Member 71 01/01/2012
Change 5d. change 1-year change 3-years change Capi.($)
+0.53%-4.80%+13.75%+61.56% 199B
+0.72%-5.86%+13.89%+218.81% 885B
+0.32%-3.23%+44.22%+56.01% 579B
-0.96%-0.85%+7.38%+50.47% 407B
-2.93%-7.03%+11.14%+27.55% 350B
-1.25%-5.55%+22.14%+55.83% 302B
-1.85%-6.70%+20.11%+33.64% 301B
-0.24%-6.49%+22.33%+4.06% 286B
-0.83%-3.37%+22.59%+79.29% 179B
-0.30%+4.20%-58.52%-51.19% 171B
Average -0.68%-3.80%+11.90%+53.60% 365.97B
Weighted average by Cap. -0.46%-4.18%+16.59%+82.54%

Financials

2026 *2027 *
Net sales 37.84B 32.62B 29.45B 28.26B 51.53B 3,477B 53.92B 348B 139B 1,667B 142B 139B 5,964B 38.75B 33.41B 30.16B 28.94B 52.76B 3,561B 55.22B 357B 143B 1,708B 145B 142B 6,107B
Net income 7.87B 6.78B 6.12B 5.87B 10.71B 723B 11.21B 72.38B 29B 347B 29.52B 28.89B 1,240B 8.61B 7.43B 6.7B 6.43B 11.73B 791B 12.27B 79.24B 31.75B 380B 32.32B 31.63B 1,357B
Net Debt 39.55B 34.1B 30.78B 29.54B 53.86B 3,635B 56.37B 364B 146B 1,743B 148B 145B 6,234B 32.94B 28.4B 25.64B 24.6B 44.86B 3,028B 46.95B 303B 121B 1,452B 124B 121B 5,193B
Logo Amgen Inc.
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows: - drug sales (95.8%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.; - other 4.2%): primarily royalties. The United States account for 71.9% of net sales.
Employees
31,500
Date Price Change Volume
06/03/26 369.53 $ +0.53% 2,443,031
05/03/26 367.60 $ -3.08% 2,870,269
04/03/26 379.27 $ +0.60% 2,028,437
03/03/26 377.00 $ -2.26% 2,710,556
02/03/26 385.70 $ -0.63% 2,838,162
Trader
Investor
Global
Quality
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
369.53USD
Average target price
350.04USD
Spread / Average Target
-5.28%

Quarterly revenue - Rate of surprise